Amgen – AstraZeneca’s Asthma Candidate Under Priority Review With FDA
The FDA has accepted for review Amgen Inc’s (NASDAQ:AMGN) marketing application seeking approval for tezepelumab to treat asthma. Amgen is developing…
AstraZeneca Announced Tezepelumab Regulatory Submission Accepted and Granted FDA Priority Review in the U.S. for Treatment of Patients With Asthma
AstraZeneca's (NYSE: AZN) Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.
COVID-19 Vaccine-Induced Blood Clots Probably Linked To Amino Acids, Study Shows: WSJ
Researchers have pointed a handful of amino acids targeted by key antibodies of some people who received the AstraZeneca…
Canadian Researchers Link Amino Acids to Blood Clots in Some People Who Received AstraZeneca Covid-19 Vaccone
-Wall Street Journal
Covid-19 Vaccine-Related Blood Clots Linked to Amino Acids in New Study
Nvidia Launches Supercomputer To Help Advance Fields Of Digital Biology, Genomics
Chip supplier Nvidia Corp (NASDAQ: NVDA) on Tuesday launched Cambridge-1, which it claims is the fastest supercomputer in the United Kingdom, dedicated to the healthcare industry.
South Korea Negotiating With mRNA COVID-19 Vaccine Makers To Produce Up To 1B Doses: Reuters
South Korea is reportedly in talks with mRNA vaccine makers, including Pfizer Inc (NYSE: PFE) and Moderna Inc (NASDAQ: MRNA), to produce COVID-19 shots in the country.
CytoSorbents Shares Are Trading Higher On Launch Of Trial On Ticagrelor Removal During Cardiothoracic Surgery
CytoSorbents Corporation (NASDAQ:CTSO) receives full FDA approval to conduct the STAR-T trial in the U.S. to support regulatory clearance of DrugSorb…
AstraZeneca Announced Receipt of Clearance from the European Commission for the Proposed Acquisition of Alexion
AstraZeneca's (NYSE: AZN) proposed acquisition of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) has achieved an important step towards completion by having cleared the European Commission review.
Attention Biotech Investors: Mark Your Calendar For July PDUFA Dates
June was a month of plenty and also turned out to be a fruitful one from the perspective of Food and Drug Administration approvals. Regulatory reviews mostly produced positive verdicts, and rejections or no-decisions were few and far between.